SCN8A and thyroid cancer, nonmedullary, 2: These observations led the authors to propose a potential new strategy for treatment of FTC patients by downregulating NaV1.6 in FTC cells which may increase the sensitivity of tumor cells to antineoplastic drugs (Li et al., 2022).